The molecular and immunological landscape of meningiomas

• Verfasst von: Lotsch, Catharina [VerfasserIn]
• Verfasst von: Warta, Rolf [VerfasserIn]
• Verfasst von: Herold-Mende, Christel [VerfasserIn]
• Titel: The molecular and immunological landscape of meningiomas
• Titelzusatz: review
• Verf.angabe: Catharina Lotsch, Rolf Warta and Christel Herold-Mende
• E-Jahr: 2024
• Jahr: 5 September 2024
• Umfang: 13 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 11.02.2025
• Weitere Titel: Titel des special issue: Biomarkers, Treatments, and Clinical Outcomes for Meningiomas and Other Skull Base Tumors
• Titel Quelle: Enthalten in: International journal of molecular sciences
• Ort Quelle: Basel : Molecular Diversity Preservation International, 2000
• Jahr Quelle: 2024
• Band/Heft Quelle: 25(2024), 17, special issue, Artikel-ID 9631, Seite 1-13
• ISSN Quelle: 1422-0067
• ISSN Quelle: 1661-6596
• DOI: doi:10.3390/ijms25179631
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: brain tumor diagnostics
• Sach-SW: DNA methylation
• Sach-SW: immunobiology
• Sach-SW: immunotherapy
• Sach-SW: infiltrating immune cells
• Sach-SW: meningioma
• Sach-SW: meningioma prognosis
• Sach-SW: molecular profiling
• K10plus-PPN: 1916868517

Abstract

Meningiomas are the most common primary intracranial tumors in adults and typically have a slow-growing and benign nature. However, there is also a substantial subset of meningiomas that shows aggressive clinical behavior and is refractory to standard treatment modalities, which are still limited to surgery and/or radiotherapy. Despite intensive research, no systemic treatment options are yet available in the clinic for these challenging tumors, resulting in poor patient outcome. Intensive research on the molecular pathogenesis of meningiomas has led to improved diagnostic tools, but so far there is no standardized implementation for the molecular profiling of these tumors for clinical practice. Recent research advances have also focused on the immunophenotyping of meningiomas, leading to several clinical trials examining the use of immune checkpoint blockade therapy in patients with clinically aggressive subtypes. In this review, we aim to summarize the current knowledge on the molecular and immunological landscape of meningiomas in detail and provide current and progressive ideas for future directions.